Cancers of the pancreas and pleura — which often have the same 9p21 deletion as some bladder cancers — also show increased sensitivity to the same drug combinations in lab models, suggesting this approach might work across multiple cancer types.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether patients with 9p21-loss pancreatic or mesothelioma tumors have improved outcomes when treated with cytarabine or PRMT5/MAT2A inhibitors compared to standard therapy.
A systematic review and meta-analysis of all published clinical trials (n≥12) evaluating cytarabine, PRMT5, or MAT2A inhibitors in patients with 9p21-loss pancreatic adenocarcinoma or mesothelioma, with standardized genetic testing, primary endpoints of overall survival and response rate, and subgroup analysis by tumor type.
An RCT could determine whether adding PRMT5 inhibitors to cytarabine improves survival in patients with 9p21-loss pancreatic adenocarcinoma.
A multicenter, double-blind RCT of 180 patients with advanced 9p21-loss pancreatic adenocarcinoma randomized to cytarabine + PRMT5 inhibitor (MRTX1719) vs. cytarabine + placebo, with primary endpoint of overall survival at 18 months, confirmed by central genetic testing.
A prospective cohort could determine whether 9p21 loss predicts improved outcomes in patients with pancreatic or mesothelioma tumors treated with these drug combinations.
A prospective cohort study following 400+ patients with advanced pancreatic adenocarcinoma or mesothelioma treated with cytarabine + PRMT5/MAT2A inhibitors, tracking response rates, toxicity, and survival over 24 months, with pre-treatment genetic profiling.
A case-control study could compare the frequency of 9p21 loss in patients with pancreatic or mesothelioma tumors who responded to these combinations versus those who did not.
A case-control study comparing 100 patients with pancreatic adenocarcinoma or mesothelioma who achieved durable response to cytarabine + PRMT5 inhibitor (≥6 months) versus 100 non-responders, matched for stage and prior therapy, with retrospective 9p21 deletion status assessed by NGS.
A cross-sectional analysis could correlate 9p21 loss with drug sensitivity in tumor cell lines from pancreatic adenocarcinoma and mesothelioma.
A cross-sectional analysis of 120+ cell lines from pancreatic adenocarcinoma and mesothelioma, measuring 9p21 deletion status and IC50 values for cytarabine and PRMT5 inhibitors, correlating with genetic and transcriptomic profiles.